Gitte-Bettina Nyvang
Overview
Explore the profile of Gitte-Bettina Nyvang including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
213
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mirza M, Bjorge L, Marme F, Christensen R, Gil-Martin M, Auranen A, et al.
Gynecol Oncol
. 2024 Dec;
192():128-136.
PMID: 39657575
Purpose: The CDK4/6 inhibitor palbociclib inhibits cyclin A, which is overexpressed in endometrial cancer. Combining palbociclib with endocrine therapy improves efficacy in hormone receptor-positive breast cancer. We investigated palbociclib combined...
2.
Kjeldsen M, Jorgensen M, Gronseth D, Schonemann-Lund M, Nyvang G, Aaquist Haslund C, et al.
Cancer Res Commun
. 2024 Nov;
4(12):3190-3200.
PMID: 39591206
The irregular response to PARPi in HRD-positive and -negative tumors highlights the need for identifying additional biomarkers. This study explores the mutational landscape beyond HRD status in AOC, ultimately advancing...
3.
Korsholm L, Kjeldsen M, Perino L, Mariani L, Nyvang G, Kristensen E, et al.
JCO Precis Oncol
. 2024 Mar;
8:e2300483.
PMID: 38427930
Purpose: To meet the urgent need for accessible homologous recombination-deficient (HRD) test options, we validated a laboratory-developed test (LDT) and a functional RAD51 assay to assess patients with ovarian cancer...
4.
Bonlokke S, Steiniche T, Sorensen B, Nyvang G, Lindegaard J, Blaakaer J, et al.
Mol Oncol
. 2023 Oct;
18(5):1231-1244.
PMID: 37853962
For cervical cancer (CC), circulating cell-free HPV DNA (ccfHPV) may establish disease severity. Furthermore, HPV integration has been correlated to viral load and survival. In this study, pre-treatment plasma from...
5.
Bonlokke S, Stougaard M, Sorensen B, Booth B, Hogdall E, Nyvang G, et al.
Cells
. 2022 Jul;
11(14).
PMID: 35883612
Circulating cell-free HPV DNA (ccfHPV DNA) may serve as a marker for cervical cancer. In this study, we used digital droplet PCR (ddPCR) to detect and quantify ccfHPV DNA in...
6.
Mirza M, Avall Lundqvist E, Birrer M, Christensen R, Nyvang G, Malander S, et al.
Lancet Oncol
. 2019 Sep;
20(10):1409-1419.
PMID: 31474354
Background: Platinum-based chemotherapy is the foundation of treatment for platinum-sensitive recurrent ovarian cancer, but has substantial toxicity. Bevacizumab and maintenance poly(ADP-ribose) polymerase (PARP) inhibitors both significantly improve efficacy versus standard...
7.
Knudsen A, Schledermann D, Nyvang G, Mogensen O, Herrstedt J
Acta Oncol
. 2016 Jan;
55 Suppl 1:65-73.
PMID: 26784001
Background: The aim of this analysis was to describe trends in incidence, mortality, prevalence, and survival in Danish women with gynecologic cancer from 1980-2012 comparing women aged 70 years or...
8.
Tanderup K, Nielsen S, Nyvang G, Pedersen E, Rohl L, Aagaard T, et al.
Radiother Oncol
. 2010 Feb;
94(2):173-80.
PMID: 20138380
Background And Purpose: Brachytherapy in locally advanced cervical cancer is still widely based on 2D standard dose planning, although 3D image guidance is available. The purpose of this study was...